

# FINALISTS 2022

## MSD's Innovation Award

This Award will acknowledge and celebrate the outstanding scientific or technological breakthrough which the judges believe has the potential to be transformative in the discovery or development of new medicines.



### **3DBio's** AuriNovo patient-matched, 3D-bioprinted living tissue ear implant

The clinical-stage regenerative medicine company 3DBio's groundbreaking approach enables the creation of living tissue implants for therapeutic applications. The company has created the first 3D-bioprinted living tissue implant and an entire suite of processes and engineering solutions required to support its AuriNovo technology platform. AuriNovo is now in the first-in-human Phase I/II clinical trial in patients with microtia, a rare congenital deformity where one or both outer ears are absent or underdeveloped.

### **BenevolentAI's** Benevolent Platform with Benevolent Knowledge Graph

BenevolentAI is combining its proprietary AI platform, scientific expertise and wet-lab facilities to allow scientists to explore interconnected disease networks to understand the complexities of biology and discover more effective medicines. Its pipeline of over 20 disease programmes spans a range of therapeutic areas. BenevolentAI delivered the first novel AI-generated chronic kidney disease target to AstraZeneca in 2021 and also discovered an target with zero prior linkage to ulcerative colitis.

### **Evonetix's** desktop platform for DNA synthesis

Inherent limitations in current methods have prevented accurate, fast, scalable DNA synthesis but Evonetix's radically different desktop platform approach builds on lessons from the semiconductor industry to deliver a step-change in DNA production that will change how DNA is accessed, made and used. This new paradigm in gene synthesis will facilitate and enable the rapidly growing field of synthetic biology and place DNA synthesis in the hands of every researcher.

### **Nucleome Therapeutics'** genome dark matter platform technology

Nucleome Therapeutics is decoding the dark matter of the human genome to uncover novel ways to treat disease. Its innovative platform enables association of disease-linked variants to gene function and facilitates new target identification and mapping of complex disease pathways. Nucleome's technology offers significant benefits over other genomics methods including the ability to work with primary cells and patient derived cells and a very high level of accuracy.

### **Orca Bio's** Orca-T cell therapy

Orca Bio is revolutionizing allogeneic hematopoietic stem cell transplants with the goal of providing better outcomes for patients who are at historically at risk of graft versus host disease. Its platform uses a precision cell selection process that sorts the more than 100 billion cells that patients would receive in a transplant down to the less than 1% that provide therapeutic benefits. From these cells, Orca Bio builds a designer immune system for patients.

# SCRIP AWARDS 2022

30 NOVEMBER 2022 · ROYAL LANCASTER, LONDON

### **Quris** BioAI Clinical Prediction Platform

The Quris BioAI platform is the first AI clinical-prediction platform that simulates clinical trials and a human body's reaction to drugs by leveraging a organ-on-chip system through the use of stem-cell derived tissue and AI to predict drug toxicity. Quris is leading a transformation in drug development speed, safety and cost that will help pharma companies avoid the risks and expense of failed clinical trials and end the reliance on ineffective animal testing.

Winners are announced at the Awards ceremony and dinner on Wednesday 30th November at the Royal Lancaster Hotel, London.